The rapid rise of GLP-1 therapies is transforming not only diabetes and obesity treatment, but also the global pharmaceutical packaging industry. According to a recent insight published by Körber, manufacturers are facing mounting pressure to scale production, strengthen supply chains, and ensure product integrity as demand for GLP-1 medications continues to surge worldwide.
Originally developed for diabetes management, GLP-1 receptor agonists have quickly become one of the pharmaceutical industry’s fastest-growing therapeutic categories, particularly in obesity care. With obesity now affecting more than one billion people globally, the demand for injectable and oral GLP-1 medications is accelerating across North America, Europe, and Asia.
This growth is creating significant challenges for pharmaceutical companies, especially in sterile manufacturing, packaging scalability, regulatory compliance, and distribution logistics. Packaging systems are now expected to do more than protect medicines ,they must also support patient safety, tamper resistance, humidity control, and high-speed global distribution.
Packaging Becomes a Strategic Differentiator
In its report, Körber highlighted that both injectable and oral GLP-1 products require highly specialized packaging approaches. Injectable therapies demand sterile, contamination-free environments, while oral formulations require advanced moisture protection and tamper-evident designs.
Bob Reilley, Vice President of Körber Pharma Packaging Materials North America, emphasized the growing importance of packaging quality in patient care, noting that pharmaceutical packaging directly impacts medicine safety and reliability.
The company’s manufacturing facility in Apex, North Carolina, has emerged as a key hub supporting the North American GLP-1 market. Through integrated engineering, automation, and quality systems, Körber says it is helping pharmaceutical companies respond to rapidly changing market demands while maintaining regulatory compliance and operational efficiency.
Lessons from the Pandemic Continue to Shape Pharma Supply Chains
Körber also referenced its experience during the COVID-19 pandemic, when it became a major supplier of vaccine cartons in the United States. The company stated that the crisis strengthened its capabilities in large-scale production, supply chain resilience, and agile manufacturing ,capabilities now being applied to the expanding GLP-1 market.
Industry experts increasingly view integrated pharmaceutical ecosystems as essential for future growth. Körber’s ecosystem approach combines aseptic processing, inspection systems, labeling, packaging automation, MES software, logistics, and consulting services into a unified platform aimed at accelerating production while maintaining quality standards.